School of Pharmacy
Recent Deposits
-
Investigating how pharmacists fit into the primary care non-medical prescribing landscape in New Zealand
Background Increasing demand for health services and resource constraints have affected access to prescribing services in primary care. Some countries, including New Zealand (NZ), have introduced non-medical prescribing ... -
Inhaled rifampicin powder formulations and their in vivo studies for clinical application in tuberculosis treatment
Background Tuberculosis (TB), a global health problem caused by Mycobacterium tuberculosis, mainly affects the lungs and spreads to other organs. Rifampicin is a potent anti-TB drug, but its oral delivery results in low ... -
Electronic Identification of Patients at High Risk for Readmission to Hospital: The EIPHRRH study
Hospital readmissions have a significant impact on the healthcare system and it has been estimated that the readmission rate in frail elderly can range from 20 to 40%, with at least 50% of these readmissions being preventable. ... -
Development of nanofibres for local delivery of neuroactive drugs to the brain
Introduction: Drug delivery to the brain to treat neurological disorders is a challenge due to the blood-brain barrier, which physically and actively restricts the transport of molecules into the brain. Implantable drug ... -
Optimising medicine information for patients in New Zealand
Background Patients must receive sufficient information about their medicines to be able to take them safely, to make informed choices, and to understand the benefits of adherence. Providing written information alongside ... -
Psychological factors associated with pharmacist involvement in patient-centered services
Pharmacists are actively being encouraged to do more patient-centred activities like medicines management, primary care for common ailments, prescribing, and vaccination as their role evolves. However, the adoption of ... -
Access to medicines and use of medicines by Māori with type 2 diabetes in Tairāwhiti
Type 2 diabetes and its associated co-morbidities have a significant impact on Māori and other indigenous populations. The prevalence of type 2 diabetes in Tairāwhiti was far greater for Māori than non-Māori (11% vs 4%). ... -
Development and preclinical evaluation of an oral therapeutic colorectal cancer vaccine
Colorectal cancer (CRC) has become the second most common cause of cancer death worldwide, indicating the need for novel therapies to reduce mortality rates and the global burden of this disease. Therapeutic subunit vaccines ... -
Pharmacometric modelling of haemodynamics in humans
Current pharmacokinetic-pharmacodynamic models describing changes to the haemodynamic system often do not include necessary feedback mechanisms. These models often provide an adequate empirical description of data but may ... -
The use of metformin in patients with renal impairment
Metformin, a biguanide, is widely accepted to be the preferred first-line oral antihyperglycaemic agent to manage type 2 diabetes. There is considerable concern that patients receiving metformin therapy may be at an increased ... -
Evaluation of intranasal particulate strategies to enhance the delivery of anti-seizure therapeutics to the brain
Epilepsy is a common and serious neurological disorder to which a high proportion of patients continue to be considered “drug-resistant” despite the availability of a host of anti-seizure drugs. Investigation into new ... -
Dabigatran etexilate dosing and monitoring in Aotearoa New Zealand
Introduction Dabigatran etexilate is a direct thrombin inhibitor that has become widely used in New Zealand. It has been available and fully subsidised in New Zealand since July 2011. Of patients who receive oral ... -
Dose adjustment based on renal function
Patients with impaired kidney function are at risk of excessive drug exposure and toxicity when standard doses of renally cleared drugs are used. Dose adjustment to normalise drug exposure between patients may be required ... -
In vitro and in vivo studies on the binding and permeation of ketotifen and norketotifen atropisomers in the central nervous system
Ketotifen (K) is a first-generation antihistamine with antiinflammatory potency. It penetrates the blood-brain barrier (BBB) and causes a sedative side effect. Norketotifen (N) is an active metabolite of K. The S-atropisomer ... -
Cell-penetrating peptides for enhanced oral delivery of nanoformulations
Introduction: Oral drug delivery systems such as polymeric nanoparticles are used to improve therapies that utilize biomacromolecules like proteins and peptides. Surface modifications of polymeric nanoparticles play a ... -
Military Medicines: ANZAC Military Pharmacy, 1914-1918
Military pharmacy is a niche subset of the wider pharmacy profession. As a small component of the armed forces, the role encompasses unique military requirements beyond usual pharmacy practice. This thesis analyses the ... -
Application of pharmacometric methods to quantify functional selectivity
Interest has arisen in the ability of ligands to differentially regulate signalling pathways when coupled to a single receptor, a concept termed functional selectivity. The current approach used to quantify functional ... -
Understanding antiepileptic drug exposure in pregnancy: the consequences for mother and child
Background: Antiepileptic drugs (AEDs) are used to manage several neurological conditions and continued use throughout pregnancy is often necessary. AED use during pregnancy has been linked to elevated obstetric risk and ... -
Non-Lamellar Liquid Crystalline Nanoparticles for Targeted Delivery of Endogenous Lipids to the Brain
Purpose: Bioactive endogenous lipids such as N-acylethanolamines (NAEs) and alkylglycerols have shown therapeutic potential in various neurological diseases and targeted brain drug delivery, respectively. However, their ... -
Scaling of clearance by body size and composition
Dose scaling is a critical component of dose individualisation that helps ensure that the required amount of drug exposure is achieved in each and every patient. This is typically achieved by scaling the pharmacokinetic ...